Commercialization

CONNECT WITH US

Blogger Facebook Twitter You Tube RSS

Medical Anti-Fungal Agent

The medicinal anti-fungal market is estimated at $4 billion annually, and as foreign countries become more industrialized and advanced, their focus on health care also increases, creating a greater need for new medicines. The increase in immunosuppressive conditions (HIV/AIDS, organ transplants) has also stimulated an increase in fungal infections. While old infectious agents had decreased in response to previous anti-fungal treatments, new resistive agents have emerged, creating a need for novel anti-fungal agents that can treat resistive fungi. Researchers at Utah State University have developed new anti-fungal agents which have are effective against a broad spectrum of both human/animal and plant pathogenic fungi. Importantly, the agents can also be specified only to fungal infections, thus they do not promote resistive bacteria production.
   
Applications
Features and Benefits
  • Synthetic antimycotic treating human/animal fungal infections:
    • Subcutaneous infection
    • Topical infections such as:
      • athlete's foot
      • ringworm
      • candidiasis
      • jock itch
  • Assisting immunosuppressive conditions
  • Novel composition with no resistive fungi evolution, creating greater levels of effectiveness
  • Lacks antibacterial activity and will not promote antibiotic resistance
  • Versatile uses and safe
 
Technology
The technology consists of novel therapeutic antifungal aminoglycoside compounds (neamine derivatives) generated from a simple and cost-effective chemistry platform. The compounds were highly effective against all 15 screened fungi, and demonstrate control of fungal pathogens in vitro. Whereas conventional aminoglycosides do promote bacterial resistance, the new compounds’ lack of antibacterial activity opens another strategy to combat the increasing problem of antibacterial resistance.
 
Development Stage
The synthesis of highly active modified neamine compounds has been recently accomplished.  USU researchers are currently working to provide additional toxicity information on the lead compounds with mice model infection studies.
 
Patent Pending
 
CONTACT INFORMATION
Berry Treat
Senior Commercialization Associate
Life Sciences
Berry.Treat@usu.edu
(435) 797-4569
Reference: W08056 (v6)
www.ipso.usu.edu

 

 

#theTemplate.getDirectEidtLink()#